A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms TRANSFORM-UK
- 07 Jun 2017 Biomarkers information updated
- 13 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 24 Nov 2016 Planned number of patients changed from 21 to 26.